1-(苯基甲氧基羰基氨基)环丙烷-1-羧酸乙酯 | 85452-41-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(苯基甲氧基羰基氨基)环丙烷-1-羧酸乙酯
• 英文名称: ethyl 1-<(benzyloxycarbonyl)amino>cyclopropanecarboxylate
• 英文别名: ethyl 1-(((benzyloxy)carbonyl)amino)cyclopropane-1-carboxylate；ethyl 1-{[(benzyloxy)carbonyl]amino}cyclopropanecarboxylate；Ethyl 1-(((benzyloxy)carbonyl)amino)cyclopropanecarboxylate；ethyl 1-(phenylmethoxycarbonylamino)cyclopropane-1-carboxylate
• CAS: 85452-41-1
• 化学式: C₁₄H₁₇NO₄
• 分子量: 263.293
• InChiKey: AJUPMRQSAXINLZ-UHFFFAOYSA-N

物化性质

• 沸点：
  394.3±31.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090
• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  1-(苯基甲氧基羰基氨基)环丙烷-1-羧酸乙酯 在 锂硼氢 、 草酰氯 、 二甲基亚砜 作用下， 以 四氢呋喃 为溶剂， 反应 21.0h， 生成 1-[(苄氧羰基)氨基]环丙烷甲醛
  参考文献：
  名称：

  Inactivation of .gamma.-aminobutyric acid aminotransferase by (S,E)-4-amino-5-fluoropent-2-enoic acid and effect on the enzyme of (E)-3-(1-aminocyclopropyl)-2-propenoic acid

  摘要：

  (S,E)-4-Amino-5-fluoropent-2-enoic acid (6) is synthesized in six steps starting from the known gamma-aminobutyric acid aminotransferase (gamma-Abu-T) inactivator, (S)-4-amino-5-fluoropentanoic acid (1). Compound 6 is a mechanism-based inactivator of gamma-Abu-T: time-dependent inactivation is saturatable and protected by substrate; thiols do not protect the enzyme from inactivation; no enzyme activity returns upon dialysis. This compound (6) binds 50 times more tightly to gamma-Abu-T than does the saturated analogue (1). No transamination of 6 occurs prior to inactivation. However, five molecules of 6 are required to inactivate the enzyme with concomitant release of five fluoride ions. Therefore, four molecules are being converted to product for each inactivation event. (E)-3-(1-Aminocyclopropyl)-2-propenoic acid is synthesized in seven steps from 1-aminocyclopropanecarboxylic acid. It is prepared as a cyclopropyl derivative of the proposed intermediate in the inactivation of gamma-Abu-T by 6. The cyclopropyl derivative, however, is a noncompetitive inhibitor and does not inactivate the enzyme. This study shows the usefulness and hazards of incorporation of a trans double bond into potential gamma-Abu-T inactivators.

  DOI：

  10.1021/jm00160a007
• 作为产物：
  描述：

  1-氯羰基环丙烷羧酸乙酯 在 sodium azide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 1-(苯基甲氧基羰基氨基)环丙烷-1-羧酸乙酯
  参考文献：
  名称：

  [EN] NUCLEOSIDE PHOSPHONATE DERIVATIVES USEFUL IN THE TREATMENT OF HIV INFECTIONS
  [FR] DERIVES DE NUCLEOSIDE PHOSPHONATE UTILES DANS LE TRAITEMENT D'INFECTIONS VIH

  摘要：

  本发明涉及通过给予由式(I)表示的核苷酸膦酸衍生物来治疗HIV感染的方法。

  公开号：

  WO2005079812A1

文献信息

• TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF
  申请人：SHANGHAI DE NOVO PHARMATECH CO LTD.

  公开号：US20140329800A1

  公开（公告）日：2014-11-06

  The present invention relates to a tri-heterocyclic derivatives, preparation process and uses thereof, specifically relates to a tri-heterocyclic derivatives of the formula (I) or a pharmaceutically acceptable salt thereof, preparation process, and further relates to a pharmaceutically acceptable composition comprising compounds of formula (I), or a pharmaceutically acceptable salt thereof, and their pharmaceutical use as inhibitors of kinase.

  本发明涉及一种三杂环衍生物，其制备过程及用途，具体涉及公式(I)的三杂环衍生物或其药学上可接受的盐，制备过程，并进一步涉及包含公式(I)化合物或其药学上可接受的盐的药学上可接受的组合物，以及它们作为激酶抑制剂的药用。
• [EN] TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF<br/>[FR] DÉRIVÉS TRIHÉTÉROCYCLIQUES, PROCÉDÉ DE PRÉPARATION ET UTILISATIONS DE CEUX-CI
  申请人：SHANGHAI DE NOVO PHARMATECH CO LTD

  公开号：WO2013091502A1

  公开（公告）日：2013-06-27

  The present invention relates to a tri-heterocyclic derivatives, preparation process and uses thereof, specifically relates to a tri-heterocyclic derivatives of the formula (I) or a pharmaceutically acceptable salt thereof, preparation process, and further relates to a pharmaceutically acceptable composition comprising compounds of formula (I), or a pharmaceutically acceptable salt thereof, and their pharmaceutical use as inhibitors of kinase.

  本发明涉及一种三杂环衍生物，其制备方法及用途，具体涉及公式(I)的三杂环衍生物或其药学上可接受的盐，制备方法，并进一步涉及包括公式(I)化合物或其药学上可接受的盐的药学上可接受的组合物，以及它们作为激酶抑制剂的药用。
• [EN] PYRROLOPYRAZINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRROLOPYRAZINE KINASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013030138A1

  公开（公告）日：2013-03-07

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及式I的新型吡咯并吡嗪衍生物的使用，其中变量如本文所述定义，其抑制JAK和SYK，并可用于治疗自身免疫和炎症性疾病。
• [EN] NOVEL ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVES, SALTS THEREOF AND PROCESS FOR THE PREPARATION OF THE SAME<br/>[FR] NOUVEAUX DERIVES DE PHOSPHONATE NUCLEOSIDIQUE ACYCLIQUE, SELS DE CES DERNIERS ET PROCEDE DE PREPARATION DE CES DERNIERS
  申请人：LG CHEM INVESTMENT LTD

  公开号：WO2002057288A1

  公开（公告）日：2002-07-25

  The present invention relates to an acyclic nucleoside phosphonate derivative, which is useful as an antiviral agent (particularly, against hepatitis B virus), pharmaceutically acceptable salts, stereoisomers, and a process for the preparation thereof.

  本发明涉及一种无环核苷酸膦酸酯衍生物，其作为抗病毒剂（特别是对乙型肝炎病毒）有用，药学上可接受的盐，立体异构体以及其制备方法。
• Nucleoside phosphonate derivatives useful in the treatment of HIV infections
  申请人：Averett R. Devron

  公开号：US20060052346A1

  公开（公告）日：2006-03-09

  The present invention relates to a method of treating HIV infections by administering a nucleoside phosphonate derivative represented by formula (1).

  本发明涉及通过给予由式（1）表示的核苷酸膦酸衍生物治疗HIV感染的方法。